Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle

Biochemical Pharmacology

Volumn 52, Issue 9, 1996, Pages 1387-1392

  Van Vliet, Arlène K ^a   Nègre Arrariou, Pascale ^a   Van Thiel, G Christa F ^a   Bolhuis, Piet A ^b   Cohen, Louis H ^a  

^a TNO   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

cell proliferation; HMG CoA reductase inhibitors; human myoblasts; lovastatin; pravastatin; simvastatin; sterol synthesis

Indexed keywords

ADENOSINE TRIPHOSPHATE; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MITOCHONDRIAL ENZYME; OXIDOREDUCTASE; PRAVASTATIN; RADIOISOTOPE; SIMVASTATIN; STEROL;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE BIOPSY; MYOBLAST; MYOPATHY; PRIORITY JOURNAL; SKELETAL MUSCLE; STEROL SYNTHESIS;

ACETIC ACID; ADENOSINE TRIPHOSPHATE; ANTICHOLESTEREMIC AGENTS; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DNA; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MITOCHONDRIA; MUSCLE, SKELETAL; OXIDOREDUCTASES; PRAVASTATIN; SIMVASTATIN; STEROLS;

EID: 0030575891     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00467-4     Document Type: Article

References (47)

1. 1. Alberts AW, Chen J, Kuron G, Hunt V, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Hensens O, Hirshfield J, Hoogstee K, Liesch J and Springer J, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol lowering agent. Proc Nad Acad Sci USA 77: 3957-3961, 1980.
2. 2. Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL and Willard AK, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: 4. side-chain ester derivatives of mevinolin. J Med Chem 29: 849-852, 1986.
3. 3. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y and Fujii S, CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of steroid synthesis and hypolipidemic effects on various animal species. Biochem Biophys Acta 877: 50-60, 1986.
4. 4. Serajuddin ATM, Ranadive SA and Mahoney EM, Relative lipophylicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharmacol Sci 80: 830-834, 1991.
5. 5. Scott WA, Hydrophilicity and the differential pharmacology of pravastatin. Lipid management: Pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. Round table ser 16: 17-25, 1990.
6. 6. Mosley ST, Kalinowski SS, Shafer BL and Tanaka RD, Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 30: 1411-1420, 1989.
7. 7. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K and Yamazaki M, Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1045: 115-120, 1990.
8. 8. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H and Tsujita Y, Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de now sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209: 315-319, 1992.
9. 9. De Vries ACJ, Vermeer A, Bloemendal H and Cohen LH, Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthamol Vis Sci 34: 377-384, 1993.
10. 10. Van Vliet AK, Van Thiel GCF, Huisman RH, Moshage H, Yap SH and Cohen LH, Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1254: 105-111, 1995.
11. 11. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C and Horiuchi S, Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43: 667-670, 1992.
12. +-independent multispecific anion transport mediates active transport of pravastatin into rat liver. Am J Physiol 264: G36-G44, 1993.
13. 13. Ziegler K and Stünkel W, Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1139: 203-209, 1992.
14. 14-Goldstein JL and Brown MS, Regulation of mevalonate pathway. Nature 343: 425-430, 1990.
15. 15. Maltese WA, Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4: 3319-3328, 1990.
16. 16. Khosravi-Far R, Cox AD, Kato K and Der CJ, Protein prenylation: key to ras function and cancer intervention? Cell Growth Diff 3: 461-469, 1992.
17. 17. Barbacid M, ras genes. Annu Rev Biochem 56: 779-827, 1987.
18. 18. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J and Sever P, Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772, 1994.
19. 19. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R and Paoletti R, Relationship between mevalonate pathway and arterial myocyte proliferations: in vitro studies with inhibitors of HMG-CoA reductase, Atherosclerosis 101: 117-125, 1993.
20. 20. Falke P, Mattiasson I, Stavenow L and Hood B, Effect of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 64: 173-176, 1989.
21. 21. Tobert JA, Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 28J-34J, 1988.
22. 22. Maher VMG, Pappu A, Illingworth DR and Thompson GR, Plasma mevalonate response in lovastatin-related myopathy. Lancet 4: 1098, 1989.
23. 23. Ayanian JZ, Fuchs CS and Stone RM, Lovastatin and rhabdomyolysis. Ann Intern Med 109: 682-683, 1988.
24. 24. East C, Alivizatos PA, Grundy SM, Jones PH and Farmer JA, Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318: 47-48, 1988.
25. 25. Walravens PA, Greene C and Frefman FE, Lovastatin, isoprenes, and myopathy. Lancet 2: 1097-1098, 1989.
26. 26. Chan PC, Robinson JD, Yeung WC, Cheng K, Yeung HW and Tsang MT, Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7: 93-99, 1992.
27. 27. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C and Scottolini AG, Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 36: 2145-2147, 1990.
28. 28. England JDF, Viles A, Walsh JC and Stewart PM, Muscle side effects associated with simvastatin therapy. Med J Austral 153: 562-563, 1990.
29. 29. Deslypere JP and Vermeulen A, Rhabdomyolysis and simvastatin. Ann Intern Med 141: 342, 1991.
30. 30. Bizzaro N, Bagolin E, Milani L, Cereser C and Finco B, Massive rhabdomyolysis and simvastatin. Clin Chem 38: 1504, 1992.
31. 31. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R and Musso JL, Rhabdomyolysis with simvastatin use. Nephron 57: 365-366, 1991.
32. 32. Schalke BB, Schmidt B, Toyka K and Hartung H, Pravastatin-associated inflammatory myopathy. New Engl J Med 327: 649-650, 1992.
33. 33. Perault MC, Ladouch-Bures L, Dejean C, Delaunay C, Pouget Abadie JF and Vandel B, Rhabdomyolysis related to ingestion of pravastatin. Therapie 48: 487, 1993.
34. 34. Decoulx E, Millaire A, De Groote P, Mahieux G and Ducloux G, Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase. Ann Cardiol Angeiol 42: 267-269, 1993.
35. 35. London SF, Gross KF and Riegel SP, Cholesterol-lowering agent myopathy (CLAM). Neurology 41: 1159-1160, 1991.
36. 36. Belo RS, Jamieson JC and Wright JA, Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts. Mol Cell Biochem 126: 159-167, 1993.
37. 37. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D and Durham SK, In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyrne A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131: 163-174, 1995.
38. 38. Carlson BM, The regeneration of skeletal muscle - a review. Am J Anat 137: 119-150, 1973.
39. 39. Yasin R, van Beers G, Nurse KCE, Al-Ani S, Landon DN and Thompson EJ, A quantitative technique for growing human adult muscle in culture starting from mononucleated cells. J Neurol Sci 32: 347-360, 1977.
40. 40. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurements with the folin reagent. J Biol Chem 193: 265-275, 1951.
41. 41. Boogaard A, Griffioen M and Cohen LH, Regulation of 3-hydroxy-3-methylglutaryl coenzyrne A reductase in human hepatoma cell line HepG2; effects of inhibitors of cholesterol synthesis on enzyme activity. Biochem J 241: 345-351, 1987.
42. 42. Bagge Hansen M, Nielsen SE and Berg K, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
43. 43. Lamprecht W and Trantschold I, Adenosin-5′-triphosphat -Bestimmung mit hexokinase und glucose-6-phosphate dehydrogenase. In: Methoden der Enzymatischen Analyse (Ed. Bergmeyer HU), pp. 2024-2033. Verlag Chemie, Weinheim, Germany, 1970.
44. 44-Brown MS and Goldstein JL, Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21: 505-517, 1980.
45. 45. Sinensky M, Beck LA, Leonard S and Evans R, Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265: 19937-19941, 1990.
46. 46. Nagata Y, Hidaka Y, Ishida F and Kamei T, Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Biochem Pharmacol 40: 843-850, 1990.
47. 47. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F and Rogers JD, Comparative pharmokinetics of lovastatin, simvastatin and pravastatin in humans. J Cli Pharmacol 32: 136-140, 1992.